Though a temporary truce was reportedly agreed upon today, there’s no doubt the Iran war has upended global supply chain management significantly, particularly for time- and temperature-critical transport sectors such as pharmaceuticals. In the below exclusive Q&A with Pharmaceutical Executive, Dan Bell, chief strategy officer for Marken UPS Healthcare Precision Logistics, shares insights on how biopharma manufacturers and their supply chain partners are navigating the fallout so far — from airspace restrictions to surging fuel costs and constrained shipping capacity.

Against the backdrop of already converging geopolitical tensions and regulatory uncertainty, Bell also discusses the impact of fluctuating US tariff enforcement on supply chain strategy and operations. That includes ramifications of the recent landmark Supreme Court decision over executive trade power and the resulting fragmented and confusing landscape for US customs compliance.